Lobbying Activity Report

1774-49807

Organization: Innovative Medicines Canada (Medicaments novateurs Canada)
Associated registration: 10310-1774-70
Lobbying Activity date: 2026-02-18
Arranged a meeting: No
Posted date: 2026-07-13

In-house lobbyists who participated in the lobbying activity: Charles Brown
Senior Public Office Holders who were lobbied in this activity: Sue Bouma, Executive Director, Clinical Services & Evaluation
Pharmaceutical, Laboratory & Blood Services Division, Health

John Capelli, Executive Director
Pharmaceutical Policy, Legislation & Engagement Branch, Health

Tijana Fazlagic, Executive Director
Therapeutic Assessment & Access Branch at BC, Health

Ian Rongve, ADM
Ministry of Health, Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Engage with the BC government to advocate for greater access to innovative medicines and vaccines for British Columbians, supportive policies to attract research and development investment, and greater collaboration to build a stronger life sciences sector and a more sustainable health system.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 COVID-19, Economic Development and Trade, Finances and Budgets, Government Procurement, Health, Industry
 
Senior officer who filed this Lobbying Activity Report: Bettina Hamelin
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Date Modified: